儿童心脏移植后严重原发性移植物功能障碍的发生率、预测因素与结局
本研究基于美国器官获取与移植网络数据库,纳入1996至2015年接受心脏移植的18岁以下儿童,并通过链接体外生命支持组织登记数据识别严重原发性移植物功能障碍(PGD)。结果显示严重PGD总体发生率为4.7%(95%CI 4.2%–5.3%),独立风险因素包括低年龄、先天性心脏病、移植时使用ECMO、较高血清胆红素及移植物缺血时间≥4小时;严重PGD患儿出院前死亡或移植物丢失率达40.6%,而无PGD者仅5.6%。
要点
- 儿童心脏移植后严重PGD发生率为4.7%,20年间无显著趋势变化。
- 独立风险因素包括低年龄、先心病、移植时ECMO支持、高胆红素及缺血时间≥4小时。
- 严重PGD患儿出院前死亡或移植物丢失率达40.6%,远高于无PGD者的5.6%。
核心结论
- 严重PGD仍是儿童心脏移植受者当前时代的重要临床并发症,并与高死亡率相关。
- 研究结果强调需要开展预防和治疗儿童心脏移植受者PGD的研究,以改善整体移植后生存。
研究设计与样本
- 研究利用美国器官获取与移植网络数据库识别1996至2015年接受心脏移植的18岁以下儿童。
- 通过将患者变量与体外生命支持组织登记数据链接,识别发生严重PGD的患儿。
- 采用逻辑回归模型评估发生严重PGD的风险因素。
主要发现
- 20年间严重PGD总体发生率为4.7%(95%CI 4.2%–5.3%)。
- 连续5年期间严重PGD发生率分别为4.1%、4.5%、5.3%和4.6%(趋势P=0.48)。
- 发生严重PGD的独立风险因素为较低年龄、先天性心脏病、移植时使用ECMO支持、较高血清胆红素及移植物缺血时间≥4小时。
- 心室辅助装置作为移植桥接及可获得的供体变量与严重PGD无关联。
- 严重PGD患儿出院前死亡或移植物丢失发生率为40.6%(105例死亡,7例再移植),无PGD患儿为5.6%。
临床怎么用
- 对于低年龄、先天性心脏病、移植时需ECMO支持、血清胆红素较高或移植物缺血时间≥4小时的儿童心脏移植受者,应警惕严重PGD风险。
- 严重PGD患儿出院前死亡或移植物丢失风险高,需加强围术期监护与及时干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous reports of primary graft dysfunction (PGD) in pediatric heart transplant (HT) recipients are limited to descriptive series of children who required extracorporeal membrane oxygenation (ECMO) support shortly after HT. In this study we sought to determine the incidence, risk factors, and survival after severe PGD in pediatric HT recipients. METHODS: We identified all children <18 years old who underwent HT in the United States during 1996 to 2015 using the Organ Procurement and Transplant Network database and then identified those who developed severe PGD by linking patient variables to Extracorporeal Life Support Organization registry data. Logistic regression models were used to assess risk factors for developing severe PGD. RESULTS: The overall incidence of severe PGD was 4.7% over 20 years (95% confidence interval 4.2% to 5.3%). The incidence was 4.1%, 4.5%, 5.3%, and 4.6%, respectively, in consecutive 5-year periods (p for trend = 0.48). Independent risk factors for developing severe PGD were younger age, congenital heart disease, HT while supported on ECMO, higher serum bilirubin, and graft ischemic time ≥4 hours. Ventricular assist device support as bridge to HT and available donor variables were not associated. Death (or graft loss) before discharge occurred in 40.6% of children with PGD (105 deaths, 7 re-transplants) and in 5.6% of children without PGD. CONCLUSIONS: Severe PGD remains an important clinical morbidity in pediatric HT recipients in the current era and is associated with high mortality. These findings highlight the need for research in preventing and treating PGD in pediatric HT recipients for improving overall post-transplant survival.
引用
- Profita EL, Gauvreau K, Rycus P, et al. Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients. J Heart Lung Transplant. 2019. PMID: 30733156. doi:10.1016/j.healun.2019.01.1310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。